Prolifagen
Prolifagen is dedicated to regenerating damaged heart muscle following a heart attack using innovative microRNA (miR) technology combined with hydrogel delivery systems. Their mission is to advance the science of miR to provide effective solutions for heart tissue regeneration, addressing a significant unmet medical need and reducing the economic burden of heart disease.
Industries
Nr. of Employees
small (1-50)
Prolifagen
3805 Old Easton Road, Suite 2242, Doylestown, PA 18902, USA
Products
miR-302 hydrogel therapeutic candidate (single-application intramyocardial formulation)
A formulation combining miR-302 with a hyaluronic-acid-based hydrogel designed for localized intramyocardial administration to release microRNA over several days and induce cardiomyocyte proliferation for heart muscle regeneration.
miR-302 hydrogel therapeutic candidate (single-application intramyocardial formulation)
A formulation combining miR-302 with a hyaluronic-acid-based hydrogel designed for localized intramyocardial administration to release microRNA over several days and induce cardiomyocyte proliferation for heart muscle regeneration.
Services
Collaborative preclinical research and development activities to design, formulate, and test microRNA-hydrogel therapeutic candidates in animal models of myocardial infarction.
Collaborative preclinical research and development activities to design, formulate, and test microRNA-hydrogel therapeutic candidates in animal models of myocardial infarction.
Expertise Areas
- Cardiac regenerative medicine
- microRNA therapeutic discovery and development
- Biomaterials-based drug delivery (hydrogels)
- Preclinical efficacy studies in small and large animal models
Key Technologies
- microRNA therapeutics (miR-302)
- Hyaluronic acid hydrogel controlled-release
- Intramyocardial delivery
- Rodent and porcine preclinical models